Naproxol is an aromatic ether in which the substituents on oxygen are 6-[(2S)-1-hydroxypropan-2-yl]-2-naphthyl and methyl. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic and an antipyretic.

Tesicam is a dioxoisoquinoline derivative patented by Pfizer, Chas. and Co., Inc. as an anti-inflammatory agent. In preclinical models, Tesicam shows potent anti-inflammatory activity against carrageenin-induced edema in rats.

Isoxepac (also known) as HP-549 is a non-steroidal anti-inflammatory drug with analgesic activity. Isoxepac was studied in the clinical trial for the treatment of postoperative pain after knee surgery for meniscectomy. It was shown, that 200 mg of isoxepac would appear to be the minimal effective dose. In case of rheumatoid arthritis, isoxepac showed significantly fewer adverse effects.

Paranyline was used in dispersible formulations of anti-inflammatory agents. Information about the current use of this drug is not available.

Salnacedin (also known as G 201) was developed as a topical anti-inflammatory agent; Salnacedin participated in phase II clinical trials in the USA for the treatment of dermatitis, acne, and psoriasis. However, all these studies were discontinued.

Piroxicam cinnamate (Cinnoxicam) is the anti-inflammatory agent. It is a cyclooxygenase inhibitor. Cinnoxicam was used in patients with inflammatory-degenerative osteoarticular diseases. The treatment brought about a significant improvement in the clinical variables considered (spontaneous pain at rest and on movement and functional limitation), which was observed within a few days of starting therapy. Tolerance was good, only a few slight side-effects having been reported. Cinnoxicam is a safe and reliable therapeutic option for men with oligoasthenospermia associated with a grade III varicocele, but surgery is better for those with grade II, IV and V. Piroxicam cinnamate as a long-acting prodrug is marketed by SPA in Italy for the treatment of rheumatic disorders.

Tesimide is an isoquinolinedione derivative patented by Warner-Lambert Co. as anti-inflammatory agent.

Sudoxicam is a nonsteroidal anti-inflammatory drug patented by American multinational pharmaceutical corporation Pfizer for the treatment of thrombosis. Sudoxicam strongly inhibited aggregation of rabbit, dog, and human platelets caused by collagen, but not by ADP. Sudoxicam inhibited the secondary phase of the biphasic response of guinea pig platelets to ADP and suppressed the release of ADP from human platelets caused by collagen. Sudoxicam shows superior anti-inflammatory activity compare to indomethacin in rat paw edema model. In clinical trials, sudoxicam was associated with several cases of severe hepatotoxicity that led to its discontinuation.

Amcinafal is an anti-inflammatory agent. It is glucocorticoid corticosteroid.

Cloticasone propionate is an ester of an antiinflammation steroid cloticasone.